Skip to main content
. 2015 Aug 22;6(29):26909–26921. doi: 10.18632/oncotarget.4817

Figure 5. Knockdown of MVA pathway genes does not sensitize breast and lung cancer cells to the anti-proliferative effects of doxorubicin.

Figure 5

A. Proliferation as assessed by measuring the doubling time using the CyQuant cell proliferation assay kit was not significantly different between cell lines expressing the SREBP2 shRNAs and control cell lines in A549, MCF7 and MDA-MB-231 cells (one-way ANOVA with Tukey post test within each shA549 cell line comparing all groups). Bars represent the mean ± SD of at least three independent experiments. B. Doxorubicin IC50 values of the A549 and MCF7 cell lines expressing the SREBP2 shRNAs were not significantly different when compared to the cell lines expressing control shRNAs.